If you have been reading about AOD-9604 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
He was less successful in persuading colleagues to centralise British space expenditure, which was split between the DTI, Defence, the Post Office and the Science Research Council – his attempt to get Margaret Thatcher, Secretary of State for Education and Science, to give up control of the latter, soured their relations. He also favoured pan European cooperation on civil aviation. Heseltine had almost daily dealings with the industrialist Arnold Weinstock, Head of GEC – as transport minister Heseltine had once summoned him in to the ministry to ask why the electronic signs on the motorway, built by GEC, did not work properly. By May 1973, Weinstock was thought by Cecil King to have a very low opinion of Heseltine, but this later improved and they became friends. Heseltine had started almost from nothing, but Haymarket had only succeeded when bought out by the big conglomerate BPC. This may explain his corporatism, in Crick's view, although unlike Jim Prior or Heath, Heseltine had never shown much interest in involving trade unions. During this period, Heseltine's opponent Stanley Clinton-Davis coined his nickname of Tarzan, due to his similarity to Johnny Weissmuller, the actor who had played Tarzan in a number of films in the 1930s and 1940s. The media were quick to follow in Clinton-Davis's example. He was caricatured as such, complete with loin-cloth, in the If series drawn by satirical political cartoonist Steve Bell.
=== Tau in Frontotemporal Lobar Degeneration (FTLD) === The tau protein is one of the most common aggregated proteins in frontotemporal lobar degeneration (FTLD), the pathology underlying FTD disorders, the other being TDP-43. While protein aggregation underlies FTLD tauopathies, the specific tau isoforms present and the morphology of the aggregates vary across subtypes. FTLD tauopathies are predominantly associated with the 3R and 4R tau isoforms. The “Pick bodies” characteristic of the FTLD tauopathy known as “Pick’s disease” is associated with 3R tau. Progressive supranuclear palsy (PSP) and corticobasal syndrome/degeneration (CBS/CBD), meanwhile, are associated with the 4R isoform. There is evidence that a ratio of 3R and 4R tau is essential for preventing neurodegeneration, and that alterations in this ratio are believed to drive FTLD and related disorders without requiring co-occurrence with other pathologies. FTD-tau appears to be sporadic in the majority of people diagnosed, but researchers do not yet fully understand the pathological mechanisms. Inherited pathogenic variants in the MAPT gene, however, are responsible for a fraction of people diagnosed with FTD-tau. Within and between families, FTD due to MAPT presents with significant heterogeneity in the symptoms that may be present, underscoring the possibility for genetic modifiers and environmental factors to influence clinical presentation. Intronic variants in MAPT, and most variants in exon 10, affect the 3R/4R tau ratio, contributing significantly to the development of FTLD pathology.
To minimize this problem, commercial supplies of THF are often stabilized with butylated hydroxytoluene (BHT). Distillation of THF to dryness is unsafe because the explosive peroxides can concentrate in the residue.
Narrated by Roger Allam, produced by Richard Melman, written, produced and directed by Chris Haws, made by InCA Productions 22 August The Emperor's New Mind, about artificial intelligence, with mathematician Roger Penrose, a play on words of the phrase Emperor's new clothes; Canadian Hans Moravec of the Robotics Institute; a scene from the edition Figure it out of the Look at Life (film series); the Mathematical Institute, University of Oxford; children of Westfields Junior School in Yateley, Hampshire, and a middle school in Oxford; crudely-operating computers were not intuitive in forming or deducing algorithms - computers could not truly understand such general rules; Euclidean tilings by convex regular polygons, and whether computers could calculate such possibilities; Gödel's incompleteness theorems; in 1974 the Arecibo Ionospheric Observatory found the Hulse–Taylor binary, the first binary pulsar found, which confirmed general relativity; wave function collapse; the cytoskeleton, microtubules and noncomputability; computers would only be able to simulate the computable parts of reasoning, and not any more.
== Notable accomplishments == She was a Fellow of the National Academy of Sciences. She also won the A.V. Rama Rao Foundation Award, the Jawaharlal Nehru Birth Centenary Visiting Fellowship, Third World Academy of Sciences Award in Chemistry in 1999 for her work in bio-organic chemistry, and the Sukh Dev Endowment Lectureship. At the time of her death, she was the most prolific organic chemist in India, having, in the last five years, a dozen publications in The Journal of the American Chemical Society, six in the Journal of Organic Chemistry and dozens in others. Her monumental contribution to the Accounts of Chemical Research was published, as well as many other papers, posthumously. She was elected Fellow of the Indian Academy of Sciences, Indian National Science Academy and the recipient of many honors the last of which was The Third World Academy of Sciences Award in chemistry for her outstanding contributions to bio-organic chemistry, particularly supramolecular assemblies, molecular design, chemical simulation of key biological processes, synthesis of functional hybrid peptides and synthesis of nanotubes, in 1999.
Sources: en.wikipedia.org
==== Non-synthesizers ==== Some mammals have lost the ability to synthesize vitamin C, including simians and tarsiers, which together make up one of two major primate suborders, Haplorhini. This group includes humans. The other more primitive primates (Strepsirrhini) have the ability to make vitamin C. Synthesis does not occur in some species in the rodent family Caviidae, which includes guinea pigs and capybaras, but does occur in other rodents, including rats and mice. Synthesis does not occur in most bat species, but there are at least two species, frugivorous bat Rousettus leschenaultii and insectivorous bat Hipposideros armiger, that retain (or regained) their ability of vitamin C production. A number of species of passerine birds also do not synthesize, but not all of them, and those that do not are not clearly related; it has been proposed that the ability was lost separately a number of times in birds. In particular, the ability to synthesize vitamin C is presumed to have been lost and then later re-acquired in at least two cases. The ability to synthesize vitamin C has also been lost in about 96% of extant fish (the teleosts). Schistosomes (parasitic flatworms) cannot synthesize vitamin C and require it from their hosts in order to produce eggs; in both guinea pigs and in mice genetically engineered to be non-synthesizers, vitamin C deficiency prevents schistosomes from reproducing. In mice, it has additionally been found that vitamin C deficiency (even intermittent) prevents schistosomes from causing disease.
=== Primary glaucoma and its variants === Primary glaucoma (H40.1-H40.2) includes primary open-angle glaucoma (chronic open-angle, chronic simple, glaucoma simplex), which can be high-tension or low-tension, and primary angle closure glaucoma (primary closed-angle, narrow-angle, pupil-block, acute congestive), which can manifest as acute, chronic, intermittent, or superimposed on chronic open-angle closure glaucoma (also called "combined mechanism" glaucoma). Other variants of primary glaucoma include:
4-Hydroxynonenal, or 4-hydroxy-2E-nonenal or 4-hydroxy-2-nonenal or 4-HNE or HNE, (C9H16O2), is an α,β-unsaturated hydroxyalkenal that is produced by lipid peroxidation in cells. 4-HNE is the primary α,β-unsaturated hydroxyalkenal formed in this process. It is a colorless oil. It is found throughout animal tissues, and in higher quantities during oxidative stress due to the increase in the lipid peroxidation chain reaction, due to the increase in stress events. 4-HNE has been hypothesized to play a key role in cell signal transduction, in a variety of pathways from cell cycle events to cellular adhesion. Early identification and characterization of 4-hydroxynonenal was reported by Esterbauer, et al., who also obtained the same compound synthetically. The topic has since been often reviewed, and one source describes the compound as "the most studied LPO (lipid peroxidation) product with pleiotropic capabilities".
== Predicting response == Trastuzumab inhibits the effects of overexpression of HER2. If the breast cancer does not overexpress HER2, trastuzumab will have no beneficial effect (and may cause harm). Doctors use laboratory tests to discover whether HER2 is overexpressed. In the routine clinical laboratory, the most commonly employed methods for this are immunohistochemistry (IHC) and either silver, chromogenic or fluorescent in situ hybridisation (SISH/CISH/FISH). HER2 amplification can be detected by virtual karyotyping of formalin-fixed paraffin embedded tumor. Virtual karyotyping has the added advantage of assessing copy number changes throughout the genome, in addition to detecting HER-2 amplification (but not overexpression). Numerous PCR-based methodologies have also been described in the literature. It is also possible to estimate HER2 copy number from microarray data. There are two FDA-approved commercial kits available for HER2 IHC; Dako HercepTest and Ventana Pathway. Fluorescent in situ hybridization (FISH) is viewed as being the "gold standard" technique in identifying patients who would benefit from trastuzumab, but it is expensive and requires fluorescence microscopy and an image capture system. The main expense involved with CISH is in the purchase of FDA-approved kits, and as it is not a fluorescent technique it does not require specialist microscopy and slides may be kept permanently. Comparative studies of CISH and FISH have shown that these two techniques show excellent correlation.
Another case was that of Ismil bin Kadar, who was initially sentenced to death for a 2005 robbery-murder case in Boon Lay, but eventually acquitted of the crime as the Court of Appeal found that based on the evidence, Ismil was not involved in the case and that it was solely his younger brother Muhammad bin Kadar who was responsible for the robbery and murder; Muhammad was subsequently executed in April 2015. Successful clemency applications are thought to be even rarer. Since 1965, the presidential clemency has been granted seven times to death row inmates, whose sentences were all commuted to life imprisonment (not counting the clemency pleas of the underaged offenders serving TPP). The most recent case was in August 2025, when convicted drug trafficker Tristan Tan Yi Rui was granted clemency by President Tharman Shanmugaratnam, who commuted Tan's death sentence to life imprisonment. Prior to Tan's pardon, the last presidential clemency to be granted was in April 1998, when President Ong Teng Cheong pardoned a 19-year-old death row inmate and convicted murderer Mathavakannan Kalimuthu, commuting his death sentence to life imprisonment. Previously, other than the Court of Appeal, offenders were allowed to file criminal or civil appeals to the Privy Council in London, where the judges could hear their appeals once they exhausted all avenues of appeal in Singapore. This avenue of appeal was fully abolished for all criminal and civil matters in April 1994. One case in which an appeal to the Privy Council was successful was the case of murderer Mohamed Yasin bin Hussin.
Sources: en.wikipedia.org
== Further reading == Arens, Sofie; Verhaegen, Jan; Verbist, Ludo (1997). "Differentiation and susceptibility ofCitrobacterisolates from patients in a university hospital". Clinical Microbiology and Infection. 3 (1): 53–57. doi:10.1111/j.1469-0691.1997.tb00251.x. ISSN 1198-743X. PMID 11864076. Janda JM, Abbott SL, Cheung WK, Hanson DF (1994). "Biochemical identification of citrobacteria in the clinical laboratory". Journal of Clinical Microbiology. 32 (8): 1850–4. doi:10.1128/JCM.32.8.1850-1854.1994. PMC 263890. PMID 7989531. Chen KJ, Chen TH, Sue YM (2013). "Citrobacter youngae and Pantoea agglomerans peritonitis in a peritoneal dialysis patient". Peritoneal Dialysis International. 33 (3): 336–7. doi:10.3747/pdi.2012.00151. PMC 3649909. PMID 23660614.
== Legality == Nicomorphine is regulated in much the same fashion as morphine worldwide but is a Schedule I controlled substance in the United States and was never introduced there. Nicomorphine may appear on rare occasions on the European black market and other channels for unsupervised opioid users. It can be produced as part of a mixture of salts and derivatives of morphine by end users by means of treating morphine with nicotinic anhydride or related chemicals in an analogue of the heroin homebake process. CAS number of hydrochloride: 35055-78-8 US DEA ACSCN: 9312 Free base conversion ratios of salts: Nicomorphine Hydrochloride: 0.93
== Operations and technology == By 2015, Lineage's facility network was ranked the second-largest in the world by the International Association of Refrigerated Warehouses. With 111 facilities in 21 states, Lineage also ranked as the second largest temperature-controlled warehousing and logistics company in the United States. In September 2020, Lineage raised $1.6 billion in equity for technology and expansion. In March 2021, Lineage raised $1.9 billion in equity for global greenfield developments, facility expansions, M&A and research and development. In July 2021, Lineage partnered with 8VC logistics technology venture capital firm, to further invest in the transportation and logistics technology sector.
Noradrenergic and serotonergic nuclei in the ARAS are involved in the regulation of the REM sleep cycle and function as "REM-off" cells, with amphetamine's effect on norepinephrine and serotonin contributing to the suppression of REM sleep and a possible reduction of cataplexy at high doses. The American Academy of Sleep Medicine (AASM) 2021 clinical practice guideline conditionally recommends dextroamphetamine for the treatment of both type 1 and type 2 narcolepsy. Treatment with pharmaceutical amphetamines is generally less preferred relative to other stimulants (e.g., modafinil) and is considered a third-line treatment option. Medical reviews indicate that amphetamine is safe and effective for the treatment of narcolepsy. Amphetamine appears to be most effective at improving symptoms associated with hypersomnolence, with three reviews finding clinically significant reductions in daytime sleepiness in patients with narcolepsy. Additionally, these reviews suggest that amphetamine may dose-dependently improve cataplexy symptoms. However, the quality of evidence for these findings is low and is consequently reflected in the AASM's conditional recommendation for dextroamphetamine as a treatment option for narcolepsy.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.